Navigation Links
BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality

JERUSALEM--(BUSINESS WIRE)--Mar 7, 2007 - BioLineRx Ltd. (TASE:BLRX), Israel's leading drug development company, reported today pre-clinical data from trials of BL-1040 demonstrating that BL-1040 is effective in preventing deterioration of the myocardium after a myocardial infarction (MI), thereby reducing left ventricle dilatation and eventual heart failure in a pig model. Professor Jonathan Leor, MD, Director of the Neufeld Cardiac Research Institute at Sheba Medical Center in Israel, presented pre-clinical data on BL-1040 at the Cardiovascular Revascularization Therapies (CRT) conference, held March 7-9, 2007 in Washington, D.C.

"We are encouraged by these results, as BL-1040 is the first injectable liquid polymer being developed to provide mechanical support to damaged heart tissues following MI. The data so far have shown that this therapy may increase cardiac performance or contractility and prevent further damage," stated Professor Leor.

"We believe there is a great unmet medical need for this product to prevent cardiac tissue damage in the risky period following heart attack," commented Morris C. Laster, MD, CEO of BioLineRx. "We look forward to advancing BL-1040 to Phase I/II trials in the second quarter of 2007 and plan to work closely with the U.S. FDA medical devices division to determine the clinical plan for BL-1040."

The data presented at the CRT conference comprised a study in 21 pigs that underwent an acute MI, and then received an intra-coronary administration of BL-1040. The results showed that BL-1040 attenuated infarct expansion and prevented left ventricle dilatation. The intracoronary administration of BL-1040 was feasible and safe, without causing arrhythmias, toxic effects or vascular obstruction.

About BL-1040

BL-1040 is a biodegradable liquid polymer intended to provide mechanical support to damaged heart tissue and increase cardiac output. BL-1040 is admin
'"/>




Page: 1 2 3

Related medicine technology :

1. BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference
2. BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming Clinical Conferences
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:2/26/2015)... WASHINGTON , Feb. 26, 2015 Legislation ... includes a pharmacy provision to help prevent inappropriate prescriptions ... The Protecting the Integrity of Medicare Act (PIMA) ... Subcommittee Chairman Kevin Brady (R-TX) and Ranking ... the prescription drug abuse epidemic and implement the right ...
(Date:2/26/2015)... , Feb. 26, 2015 Research and Markets ... the "Radiation Therapy Equipment - Global Strategic Business ... This report analyzes the worldwide markets for Radiation Therapy ... Linear Accelerator, Treatment Planning Systems, and Radiation Therapy Simulator. ... Canada , Japan ...
(Date:2/26/2015)... 2015  Spring Bank Pharmaceuticals, Inc., a clinical-stage ... of virus infections, today announced that Jonathan ... President of Finance, a newly created role.  Mr. ... activities, including financial planning and reporting, accounting and ... Jensen , President and CEO. ...
Breaking Medicine Technology:PCMA Statement on the 'Protecting the Integrity of Medicare Act' 2Radiation Therapy Equipment - Global Strategic Business Report 2015-2020: Linear Accelerator, Treatment Planning Systems, and Radiation Therapy Simulator 2Jonathan P. Freve, CPA, Joins Spring Bank Pharmaceuticals as Vice President of Finance 2
(Date:2/27/2015)... February 27, 2015 Muscular Dystrophy ... Biomedical Engineering at Duke University, recently announced a ... and young men with Duchenne muscular dystrophy (DMD). ... Communications, and Gersbach will discuss their implications at ... 11-14 in Washington, D.C. , Background: Gersbach ...
(Date:2/27/2015)... According to the report, the annual revenue ... in 2013 rose by 31.9%. However, in the first ... generated by the industry was recorded at RMB3.623 billion ... industry in 2013. , View Full Report at ... oral industry as a branch of medical industry that ...
(Date:2/27/2015)... Lake City, UT (PRWEB) February 27, 2015 ... Best and Worst Commuter Cities in Florida " ... traffic data from the 2013 U.S. Census Bureau ... 10,000 at the time of the survey. , ... city level, including methods of commuting and a ...
(Date:2/27/2015)... On time and under budget, the doors ... Inside and out, the nearly 900,000-square-foot facility makes good ... the tornado-ravaged St. John’s Regional Medical Center with a ... just 46 months after the tornado hit Joplin, which ... to plan, design and construct a similarly sized hospital,” ...
(Date:2/27/2015)... Fairfax, VA (PRWEB) February 27, 2015 ... currently accepting applications for its next class of Fellows ... the field of radiology business management. , Since ... the significant contributions made by RBMA members to the ... is a prestigious recognition because each Fellow candidate must ...
Breaking Medicine News(10 mins):Health News:Statement: New MDA-Funded Genetic Therapy Technique Targets DMD 2Health News:China Dental Industry to Expand Rapidly Owing to the Evolution of Medical and Healthcare Systems: MarketResearchReports.Biz 2Health News:China Dental Industry to Expand Rapidly Owing to the Evolution of Medical and Healthcare Systems: MarketResearchReports.Biz 3Health News:40 Best and Worst Commuter Cities in Florida Announced by Obrella 2Health News:New Hospital Built to Stand Against Nature 2Health News:New Hospital Built to Stand Against Nature 3Health News:New Hospital Built to Stand Against Nature 4Health News:RBMA Issues Call for Fellowship Applicants 2
... with rheumatoid arthritis who undergo total knee replacement ... according to a new study by researchers at ... City. These reduced expectations, which may be unnecessary, ... postsurgical rehabilitation leading to worse outcomes, say doctors. ...
... , SATURDAY, Nov. 5 (HealthDay News) -- Exposure to certain ... for the painful joint disease known as rheumatoid arthritis, new ... one of the six most common air pollutants in the ... to be presented Wednesday at the American College of Rheumatology ...
... HealthDay Reporter , FRIDAY, Nov. 4 (HealthDay News) -- A ... identifying a gene that is critical in determining which life-saving ... by Genomic Health, results in a number of false-negatives for ... in the Journal of Clinical Oncology . ...
... Cholesterol-lowering medications may help millions fight heart ... control, according to a study presented at the American ... Boston, Nov. 3-8. In the preliminary study ... medication or statins, to 20 patients with asthma who ...
... lab cultures and mice, Johns Hopkins scientists have found that ... causes colon inflammation and increases activity of a gene ... is to expose the gut to hydrogen peroxide the ... cause DNA damage, contributing to the formation of colon tumors, ...
... role in kidney failure, and blocking the action of this ... according to researchers. "We believe these arginase inhibitors may ... the progression of, or even prevent the development of, end-stage ... Penn State College of Medicine. In the United States diabetes ...
Cached Medicine News:Health News:Rheumatoid arthritis patients have low expectations after knee replacement surgery 2Health News:Rheumatoid arthritis patients have low expectations after knee replacement surgery 3Health News:Studies Suggest Link Between Smog, Joint Disease 2Health News:Common Breast Cancer Gene Test May Be Flawed, Study Says 2Health News:Common Breast Cancer Gene Test May Be Flawed, Study Says 3Health News:ACAAI Annual Meeting abstracts: Improved outcomes for adults with allergies and asthma 2Health News:ACAAI Annual Meeting abstracts: Improved outcomes for adults with allergies and asthma 3Health News:ACAAI Annual Meeting abstracts: Improved outcomes for adults with allergies and asthma 4Health News:Common bacteria cause some colon tumors by altering peroxide-producing gene 2Health News:Research aims to prevent diabetic kidney failure 2
The Foundation PS knee offers a femoral option and tibial insert which provides a specially designed cam action that engages at 60 degrees of flexion to induce a smooth stable femoral roll-back motio...
Consensus Knee implants are designed to provide both joint and implant stability and allow near normal kinematics. The components are anatomic with porous and nonporous options. Six femoral/tibial an...
Scorpio CR Knee is designed to address normal knee kinematics, range of motion (ROM) and polyethylene wear....
... The TC-PLUS Solution tricompartmental total knee ... with knee arthroplasty. State-of-the-art design and manufacturing ... achieve optimum biomechanical function as well as ... polyethylene tibial insert to keep wear to ...
Medicine Products: